Summary

The global companion diagnostic market is projected to reach a value of USD 25,300.58 million by 2035, reflecting strong growth momentum over the forecast period. Expanding at a CAGR of 12.68% from 2025 to 2035, the market is being driven by the increasing adoption of personalized medicine and targeted therapies.

Surging Burden of Cancer and Chronic Diseases
The rapidly increasing incidence of cancer and chronic conditions worldwide is a primary driver of the global companion diagnostics market, as it intensifies the need for precision medicine and targeted treatment strategies. This growing disease burden is accelerating the adoption of biomarker-based diagnostics to improve clinical outcomes and optimize therapy selection.

Segment-wise Snapshot of the Market
- HER2 Testing - Guides targeted breast cancer therapy decisions
- PD-1 Testing - Enables immunotherapy response assessment in cancers
- EGFR Mutation Testing - Identifies lung cancer targeted treatment suitability
- ALK Rearrangement Testing - Detects gene fusions for precision oncology
- Others (Test Type) - Covers emerging biomarker-based diagnostic assays
- Assays - Core diagnostic tools for biomarker detection
- Reagents & Kits - Essential consumables supporting diagnostic testing workflows
- Instruments/Systems - Platforms enabling accurate and efficient diagnostics
- Software & Services - Data analysis and clinical support solutions
- PCR - Rapid amplification for sensitive genetic mutation detection
- NGS - High-throughput sequencing for comprehensive genomic profiling
- IHC - Protein expression analysis in tissue-based diagnostics
- FISH - Detects chromosomal abnormalities using fluorescent probes
- Others (Technology) - Includes advanced and hybrid diagnostic technologies
- Cancer - Dominant application driven by rising global incidence
- Neurological Disorders - Supports diagnosis of complex brain conditions
- Cardiovascular Disorders - Enables risk assessment and targeted treatments
- Infectious Disease - Assists in pathogen detection and therapy selection
- Biopharmaceutical and Biotechnology Companies - Drive co-development of targeted therapies
- CROs and CDMOs - Provide outsourced research and manufacturing support
- Others (End User) - Includes hospitals, diagnostic labs, and research institutes

Regional Growth Overview
North America dominates due to a rising cancer survivor base and strong regulatory support accelerating companion diagnostics adoption. Europe and Asia Pacific are witnessing rapid growth driven by stricter regulations, expanding clinical evidence, and increasing cancer burden.

Strategic Launch of Clinical-Grade dPCR Platform
In September 2024, QIAGEN introduced the QIAcuityDx, a clinical-grade digital PCR system designed for oncology and liquid biopsy applications, offering precise quantitation of low-abundance DNA/RNA. With regulatory alignment under U.S. 510(k) exemption and Europe's IVDR, the platform strengthens its companion diagnostics pipeline through enhanced workflow integration and expanding pharma partnerships.

Expansion into Non-Oncology Therapeutic Areas
The global companion diagnostics market is gaining a strategic edge by expanding beyond oncology into metabolic, cardiovascular, and rare genetic diseases, significantly broadening its application scope. This shift is unlocking new growth avenues as biomarker-driven approaches begin addressing a wider patient population.

Key Report Attributes
- Market Size 2035: USD 25,300.58 Million
- CAGR (2025-2035): 12.68%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Test Type: HER2 Testing - 10.90%, PD-1 Testing - 12.03%.
- By Products & Ser5vices: Assays - 12.27%, Reagents & Kits - 12.99%.
- By Technology: Polymerase Chain Reaction (PCR) -12.95%, Next-Generation Sequencing (NGS) - 13.91%.
- By Indication: Cancer - 12.67%, Neurological Disorders - 11.93%.
- By End User: Biopharmaceutical and Biotechnology Companies - 12.35%, CROs and CDMOs - 13.91%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ............. 20
2 MARKET INTRODUCTION .......... 22
2.1 DEFINITION ........ 22
2.2 SCOPE OF THE STUDY ......... 22
2.3 RESEARCH OBJECTIVE ....... 22
2.4 MARKET STRUCTURE ......... 23
3 RESEARCH METHODOLOGY ........... 25
3.1 OVERVIEW .......... 25
3.2 DATA FLOW ........ 27
3.2.1 DATA MINING PROCESS .......... 27
3.3 PURCHASED DATABASE: ........... 28
3.4 SECONDARY SOURCES: ....... 29
3.4.1 SECONDARY RESEARCH DATA FLOW: ........... 30
3.5 PRIMARY RESEARCH: .......... 31
3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 32
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .......... 33
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ....... 34
3.6.1 REVENUE ANALYSIS APPROACH ............ 34
3.7 DATA FORECASTING............ 35
3.7.1 DATA FORECASTING TYPE ....... 35
3.8 DATA MODELING ............ 36
3.8.1 MICROECONOMIC FACTOR ANALYSIS: .......... 36
3.8.2 DATA MODELING: ............. 37
3.9 TEAMS AND ANALYST CONTRIBUTION ......... 39
4 MARKET DYNAMICS ........... 41
4.1 INTRODUCTION ........ 41
4.2 DRIVERS ........ 42
4.2.1 RISING CANCER & CHRONIC DISEASE PREVALENCE ........... 42
4.2.2 GROWING ADOPTION OF TARGETED THERAPIES AND PRECISION MEDICINE .......... 43
4.2.3 TECHNOLOGICAL ADVANCES ......... 43
4.2.4 INCREASING DRUG–DIAGNOSTIC CO-DEVELOPMENT & REGULATORY APPROVALS ....... 44
4.3 RESTRAINTS ............. 45
4.3.1 HIGH COST & CAPITAL INVESTMENT FOR CDX DEVELOPMENT AND TESTING ........ 45
4.3.2 REGULATORY COMPLEXITY AND VARIED APPROVAL PATHWAYS ............ 45
4.3.3 LIMITED REIMBURSEMENT, UNEVEN ACCESS & AWARENESS ............ 45
4.4 OPPORTUNITIES ............. 47
4.4.1 EXPANSION BEYOND ONCOLOGY INTO OTHER THERAPEUTIC AREAS ............. 47
4.4.2 GROWTH IN BIOINFORMATICS, SOFTWARE & SERVICES SUPPORTING CDX............. 47
5 MARKET FACTOR ANALYSIS ........... 49
5.1 PORTER'S FIVE FORCES MODEL ........... 49
5.1.1 THREAT OF NEW ENTRANTS ........... 49
5.1.2 BARGAINING POWER OF SUPPLIERS ............. 50
5.1.3 THREAT OF SUBSTITUTES ....... 50
5.1.4 BARGAINING POWER OF BUYERS ........... 50
5.1.5 INTENSITY OF RIVALRY ........... 50
5.2 IMPACT ANALYSIS OF COVID-19 .......... 51
5.2.1 DISRUPTION IN DIAGNOSTIC TESTING AND ONCOLOGY PROCEDURES ............ 51
5.2.2 SUPPLY CHAIN DISRUPTIONS ......... 51
5.2.3 CHANGES IN PATIENT BEHAVIOR AND CLINICAL WORKFLOWS ......... 51
5.2.4 IMPACT ON R&D AND INNOVATION ........ 52
5.3 COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO ......... 53
5.4 PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION) ............ 55
5.5 MARKET SHARE BY DRUG GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%) ......... 55
5.5.1 GLOBAL MARKET SHARE BY DRUG, 2024 (%) ........ 55
5.5.2 NORTH AMERICA MARKET SHARE BY DRUG, 2024 (%) ........ 56
5.5.2.1 US MARKET SHARE BY DRUG, 2024 (%) ........ 56
5.5.3 EUROPE MARKET SHARE BY DRUG, 2024 (%) ........ 57
5.5.3.1 GERMANY MARKET SHARE BY DRUG, 2024 (%) ........... 57
5.5.3.2 UK MARKET SHARE BY DRUG, 2024 (%) ........ 58
5.5.4 ASIA-PACIFIC MARKET SHARE BY DRUG, 2024 (%) ....... 58
5.5.4.1 CHINA MARKET SHARE BY DRUG, 2024 (%) ......... 59
5.5.4.2 INDIA MARKET SHARE BY DRUG, 2024 (%) ........... 59
5.5.4.3 JAPAN MARKET SHARE BY DRUG, 2024 (%) ......... 60
5.6 MARKET SHARE BY CLONE GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%) ....... 61
5.6.1 GLOBAL MARKET SHARE BY CLONE, 2024 (%) ............. 61
5.6.2 NORTH AMERICA MARKET SHARE BY CLONE, 2024 (%) ............. 61
5.6.2.1 US MARKET SHARE BY CLONE, 2024 (%) ............. 62
5.6.3 EUROPE MARKET SHARE BY CLONE, 2024 (%) ............. 62
5.6.3.1 GERMANY MARKET SHARE BY CLONE, 2024 (%) ......... 63
5.6.3.2 UK MARKET SHARE BY CLONE, 2024 (%) ............. 63
5.6.4 ASIA-PACIFIC MARKET SHARE BY CLONE, 2024 (%) ............ 64
5.6.4.1 INDIA MARKET SHARE BY CLONE, 2024 (%) ......... 64
5.6.4.2 JAPAN MARKET SHARE BY CLONE, 2024 (%) ....... 65
5.7 QUALITATIVE ANALYSIS OF PD-L1 TESTING CUT-OFFS ............. 66
5.8 PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION .......... 67
5.9 PRICING ANALYSIS, 2024 (USD) ............ 67
6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE ........... 69
6.1 OVERVIEW .......... 69
6.2 HER2 TESTING ......... 72
6.3 PD-1 TESTING ............ 73
6.4 EGFR MUTATION TESTING ............. 74
6.5 ALK REARRANGEMENT TESTING ....... 74
6.6 OTHERS ......... 74
7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES ......... 76
7.1 OVERVIEW .......... 76
7.2 ASSAYS, REAGENTS & KITS ............ 78
7.3 INSTRUMENTS/SYSTEMS ........ 78
7.4 SOFTWARE & SERVICES ............ 79
8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY ............ 80
8.1 OVERVIEW .......... 80
8.2 POLYMERASE CHAIN REACTION (PCR) ........... 82
8.3 NEXT-GENERATION SEQUENCING (NGS) ........ 82
8.4 IMMUNOHISTOCHEMISTRY (IHC) ....... 83
8.5 FLUORESCENCE IN-SITU HYBRIDIZATION (FISH)............. 83
8.6 OTHERS ......... 83
9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION .......... 84
9.1 OVERVIEW .......... 84
9.2 CANCER......... 86
9.3 NEUROLOGICAL DISORDERS ............ 87
9.4 CARDIOVASCULAR DISORDERS............. 87
9.5 INFECTIOUS DISEASES ........ 88
10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER ............ 89
10.1 OVERVIEW .......... 89
10.2 BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ............ 91
10.3 CROS AND CDMOS .......... 91
10.4 OTHERS ......... 92
11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION ......... 93
11.1 OVERVIEW .......... 93
11.2 NORTH AMERICA ........... 95
11.2.1 US........ 102
11.2.2 CANADA ............ 106
11.3 EUROPE ......... 111
11.3.1 GERMANY .......... 119
11.3.2 FRANCE ............. 123
11.3.3 UK ....... 127
11.3.4 ITALY .......... 131
11.3.5 SPAIN ......... 135
11.3.6 DENMARK .......... 139
11.3.7 FINLAND ............ 143
11.3.8 ICELAND ............ 147
11.3.9 NORWAY ............ 151
11.3.10 SWEDEN ............ 155
11.3.11 REST OF EUROPE ....... 159
11.4 ASIA-PACIFIC ............ 164
11.4.1 INDIA .......... 172
11.4.2 JAPAN ........ 176
11.4.3 SOUTH KOREA ........... 180
11.4.4 AUSTRALIA ........ 184
11.4.5 REST OF ASIA-PACIFIC ............ 188
12 COMPETITIVE LANDSCAPE ............. 193
12.1 INTRODUCTION ........ 193
12.2 MARKET SHARE ANALYSIS, 2024 ....... 193
12.3 COMPETITOR DASHBOARD....... 194
12.4 PUBLIC PLAYERS STOCK SUMMARY ........ 195
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ........ 195
12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ........ 196
12.1.1 PRODUCT/SERVICE LAUNCH ........... 196
12.1.2 ACQUISITION ............ 197
12.1.3 ACCREDITATION ....... 198
12.1.4 COLLABORATION/ PARTNERSHIP .......... 199
13 COMPANY PROFILES ......... 200
13.1 QIAGEN .......... 200
13.1.1 COMPANY OVERVIEW ....... 200
13.1.2 FINANCIAL OVERVIEW ............. 201
13.1.3 PRODUCTS OFFERED ........ 202
13.1.4 KEY DEVELOPMENTS ........ 202
13.1.5 SWOT ANALYSIS ....... 203
13.1.6 KEY STRATEGIES ....... 204
13.2.4 PRODUCTS OFFERED ........ 208
13.2.6 SWOT ANALYSIS ....... 209
13.3 BIOMÉRIEUX ............. 211
13.3.1 COMPANY OVERVIEW ....... 211
13.3.2 FINANCIAL OVERVIEW ............. 212
13.3.3 PRODUCTS OFFERED ........ 213
13.3.4 KEY DEVELOPMENTS ........ 214
13.3.5 SWOT ANALYSIS ....... 215
13.3.6 KEY STRATEGIES ....... 215
13.4 LEICA BIOSYSTEMS NUSSLOCH GMBH ............ 216
13.4.1 COMPANY OVERVIEW ....... 216
13.4.2 FINANCIAL OVERVIEW ............. 216
13.4.3 PRODUCTS OFFERED ........ 217
13.4.4 KEY DEVELOPMENTS ........ 217
13.4.5 KEY STRATEGIES ....... 217
13.5 NG BIOTECH ....... 218
13.5.1 COMPANY OVERVIEW ....... 218
13.5.2 FINANCIAL OVERVIEW ............. 219
13.5.3 PRODUCTS OFFERED ........ 219
13.5.5 KEY STRATEGIES ....... 219
13.6 THERMO FISHER SCIENTIFIC INC. ....... 220
13.6.1 COMPANY OVERVIEW ....... 220
13.6.2 FINANCIAL OVERVIEW ............. 221
13.6.3 PRODUCTS OFFERED ........ 222
13.6.4 KEY DEVELOPMENTS ........ 222
13.6.5 SWOT ANALYSIS ....... 223
13.6.6 KEY STRATEGY .......... 223
13.7 ILLUMINA, INC. ........ 224
13.7.1 COMPANY OVERVIEW ....... 224
13.7.2 FINANCIAL OVERVIEW ............. 225
13.7.3 PRODUCTS OFFERED ........ 226
13.7.4 KEY DEVELOPMENTS ........ 226
13.7.5 KEY STRATEGIES ....... 227
13.8 AGILENT TECHNOLOGIES, INC. ............. 228
13.8.1 COMPANY OVERVIEW ....... 228
13.8.2 FINANCIAL OVERVIEW ............. 229
13.8.3 PRODUCTS OFFERED ........ 230
13.8.4 KEY DEVELOPMENTS ........ 230
13.8.5 SWOT ANALYSIS ....... 231
13.8.6 KEY STRATEGIES ....... 231
13.9 FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD ) ............. 232
13.9.1 COMPANY OVERVIEW ....... 232
13.9.2 FINANCIAL OVERVIEW ............. 233
13.9.3 PRODUCTS OFFERED ........ 234
13.9.4 KEY DEVELOPMENTS ........ 234
13.9.5 KEY STRATEGIES ....... 234
13.10 MYRIAD GENETICS, INC. ............ 235
13.10.1 COMPANY OVERVIEW ....... 235
13.10.2 FINANCIAL OVERVIEW ............. 236
13.10.3 PRODUCTS OFFERED ........ 236
13.10.4 KEY DEVELOPMENTS ........ 237
13.10.5 KEY STRATEGIES ....... 237
14 DATA CITATIONS ......... 238

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 38
TABLE 2 COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO 53
TABLE 3 PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION) 55
TABLE 4 PD-L1 TESTING CUT-OFFS 66
TABLE 5 PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION 67
TABLE 6 PRICING ANALYSIS, 2024 (USD) 67
TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION) 70
TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (TEST VOLUME) 71
TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (USD MILLION) 72
TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (TEST VOLUME) 72
TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION) 77
TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION) 81
TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 & 2035 (USD MILLION) 85
TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 & 2035 (USD MILLION) 90
TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (USD MILLION) 93
TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (TEST VOLUME) 94
TABLE 17 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 97
TABLE 18 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) 98
TABLE 19 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) 99
TABLE 20 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION) 99
TABLE 21 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME) 100
TABLE 22 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION) 100
TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 101
TABLE 24 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION) 101
TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION) 102
TABLE 26 US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) 102
TABLE 27 US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) 103
TABLE 28 US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION) 103
TABLE 29 US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME) 104
TABLE 30 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION) 104
TABLE 31 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 105
TABLE 32 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION) 105
TABLE 33 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION) 106
TABLE 34 CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) 106
TABLE 35 CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) 107
TABLE 36 CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION) 107
TABLE 37 CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME) 108
TABLE 38 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION) 108
TABLE 39 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 109
TABLE 40 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION) 109
TABLE 41 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION) 110
TABLE 42 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 113
TABLE 43 EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-H-2035 (TEST VOLUME) 114
TABLE 44 EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 115
TABLE 45 EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 116
TABLE 46 EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 116
TABLE 47 EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 117
TABLE 48 EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 117
TABLE 49 EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 118
TABLE 50 EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 118
TABLE 51 EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 119
TABLE 52 GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 119
TABLE 53 GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 120
TABLE 54 GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 120
TABLE 55 GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 121
TABLE 56 GERMANY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 121
TABLE 57 GERMANY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 122
TABLE 58 GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 122
TABLE 59 GERMANY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 123
TABLE 60 FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 123
TABLE 61 FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 124
TABLE 62 FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 124
TABLE 63 FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 125
TABLE 64 FRANCE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 125
TABLE 65 FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 126
TABLE 66 FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 126
TABLE 67 FRANCE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 127
TABLE 68 UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 127
TABLE 69 UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 128
TABLE 70 UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 128
TABLE 71 UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 129
TABLE 72 UK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 129
TABLE 73 UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 130
TABLE 74 UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 130
TABLE 75 UK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 131
TABLE 76 ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 131
TABLE 77 ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 132
TABLE 78 ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 132
TABLE 79 ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 133
TABLE 80 ITALY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 133
TABLE 81 ITALY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 134
TABLE 82 ITALY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 134
TABLE 83 ITALY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 135
TABLE 84 SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 135
TABLE 85 SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 136
TABLE 86 SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 136
TABLE 87 SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 137
TABLE 88 SPAIN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 137
TABLE 89 SPAIN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 138
TABLE 90 SPAIN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 138
TABLE 91 SPAIN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 139
TABLE 92 DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 139
TABLE 93 DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 140
TABLE 94 DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 140
TABLE 95 DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 141
TABLE 96 DENMARK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 141
TABLE 97 DENMARK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 142
TABLE 98 DENMARK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 142
TABLE 99 DENMARK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 143
TABLE 100 FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 143
TABLE 101 FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 144
TABLE 102 FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 144
TABLE 103 FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 145
TABLE 104 FINLAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 145
TABLE 105 FINLAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 146
TABLE 106 FINLAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 146
TABLE 107 FINLAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 147
TABLE 108 ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 147
TABLE 109 ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 148
TABLE 110 ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 148
TABLE 111 ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 149
TABLE 112 ICELAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 149
TABLE 113 ICELAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 150
TABLE 114 ICELAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 150
TABLE 115 ICELAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 151
TABLE 116 NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 151
TABLE 117 NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 152
TABLE 118 NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 152
TABLE 119 NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 153
TABLE 120 NORWAY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 153
TABLE 121 NORWAY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 154
TABLE 122 NORWAY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 154
TABLE 123 NORWAY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 155
TABLE 124 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 155
TABLE 125 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 156
TABLE 126 SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 156
TABLE 127 SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 157
TABLE 128 SWEDEN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 157
TABLE 129 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 130 SWEDEN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 131 SWEDEN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 132 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
TABLE 133 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 134 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 135 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 136 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 137 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 138 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 139 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 140 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 141 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (TEST VOLUME)
TABLE 142 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
TABLE 143 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
TABLE 144 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 145 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 146 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 147 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 148 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 149 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 150 INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
TABLE 151 INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
TABLE 152 INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 153 INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 154 INDIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 155 INDIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 156 INDIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 157 INDIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 158 JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
TABLE 159 JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
TABLE 160 JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 161 JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 162 JAPAN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 163 JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 164 JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 165 JAPAN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 166 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
TABLE 167 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
TABLE 168 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 169 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 170 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 171 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 172 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 173 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 174 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
TABLE 175 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
TABLE 176 AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 177 AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 178 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 179 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 180 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 181 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 182 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
TABLE 183 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
TABLE 184 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
TABLE 185 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
TABLE 186 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
TABLE 187 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
TABLE 188 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
TABLE 189 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
TABLE 190 PRODUCT/SERVICE LAUNCH
TABLE 191 ACQUISITION/EXPANSION
TABLE 192 ACCREDITATION
TABLE 193 COLLABORATION/ PARTNERSHIP
TABLE 194 QIAGEN: PRODUCTS AND SERVICES OFFERED
TABLE 195 QIAGEN: KEY DEVELOPMENTS
TABLE 196 BIO-TECHNE: PRODUCTS AND SERVICES OFFERED
TABLE 197 BIOMÉRIEUX: PRODUCTS AND SERVICES OFFERED
TABLE 198 BIOMÉRIEUX: PRODUCTS OFFERED
TABLE 199 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED
TABLE 200 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED
TABLE 201 NG BIOTECH: PRODUCTS OFFERED
TABLE 202 THERMO FISHER SCIENTIFIC INC.: PRODUCTS AND SERVICES OFFERED
TABLE 203 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
TABLE 204 ILLUMINA, INC.: PRODUCTS AND SERVICES OFFERED
TABLE 205 ILLUMINA, INC.: KEY DEVELOPMENTS
TABLE 206 AGILENT TECHNOLOGIES, INC.: PRODUCTS AND SERVICES OFFERED
TABLE 207 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS
TABLE 208 FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD ): PRODUCTS AND SERVICES OFFERED
TABLE 209 MYRIAD GENETICS, INC.: PRODUCTS AND SERVICES OFFERED
TABLE 210 MYRIAD GENETICS, INC.: KEY DEVELOPMENTS